Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation
Top Cited Papers
- 18 August 2015
- journal article
- Published by Elsevier BV in American Journal of Obstetrics and Gynecology
- Vol. 214 (1), 103.e1-103.e12
- https://doi.org/10.1016/j.ajog.2015.08.034
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Early Administration of Low-Dose Aspirin for the Prevention of Preterm and Term Preeclampsia: A Systematic Review and Meta-AnalysisFetal Diagnosis and Therapy, 2011
- pROC: an open-source package for R and S+ to analyze and compare ROC curvesBMC Bioinformatics, 2011
- Turning the Pyramid of Prenatal CareFetal Diagnosis and Therapy, 2011
- Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trialThe Lancet, 2009
- First‐trimester maternal serum pregnancy‐associated plasma protein‐A and pre‐eclampsiaUltrasound in Obstetrics & Gynecology, 2008
- Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsiaUltrasound in Obstetrics & Gynecology, 2008
- Mean Arterial Pressure at 11 +0 to 13 +6 Weeks in the Prediction of PreeclampsiaHypertension, 2008
- Prediction of pre‐eclampsia by uterine artery Doppler imaging: relationship to gestational age at delivery and small‐for‐gestational ageUltrasound in Obstetrics & Gynecology, 2008
- Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysisBMJ, 2007
- The Classification and Diagnosis of the Hypertensive Disorders of Pregnancy: Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP)Hypertension in Pregnancy, 2001